Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease
Objective. To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with immunoglobulin-G4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-01-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://www.reumatismo.org/reuma/article/view/1744 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591097086345216 |
|---|---|
| author | Linda Mastromanno Federico Giardina Angelica Gattamelata Serena Colafrancesco Simona Truglia Francesca Romana Spinelli Edoardo Simoncelli Bruno Lucchino Fabrizio Conti Roberta Priori |
| author_facet | Linda Mastromanno Federico Giardina Angelica Gattamelata Serena Colafrancesco Simona Truglia Francesca Romana Spinelli Edoardo Simoncelli Bruno Lucchino Fabrizio Conti Roberta Priori |
| author_sort | Linda Mastromanno |
| collection | DOAJ |
| description |
Objective. To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with immunoglobulin-G4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-CoV-2 infection in IgG4-RD patients.
Methods. Patients with IgG4-RD in follow-up before the onset of the SARS-CoV-2 pandemic were contacted by telephone and asked to answer an ad hoc questionnaire regarding their vaccination status against SARS-CoV-2 and related AEs following vaccination. The occurrence and the outcome of SARS-CoV-2 infection were also recorded. The same questionnaire was proposed to healthy controls (HC).
Results. 20 patients and 40 HC were enrolled. In the patient’s cohort, 90% were vaccinated with at least one dose; among them, 9 reported AEs: 44.4% systemic and 22.2% local. Within the HC group, 100% were vaccinated with at least one dose. 13 out of 40 HC had systemic AEs (50%), and 27 (67.5%) reported local AEs. Neither in IgG4-RD nor in HC, serious adverse reactions were observed. Among the patient’s cohort, 60% contracted SARS-CoV-2 infection, and 41.67% were on immunosuppressants at the time of the infection. One patient presented with severe COVID-19. No disease flares following vaccination or infection were reported.
Conclusions. Results from our study indicate a good adherence to the vaccination campaign against SARS-CoV-2 in patients with IgG4-RD and support a relatively good safety profile of this vaccine. Compared to controls, patients with IgG4-RD reported slightly more systemic AEs and fewer local AEs. A similar rate of COVID-19 development was observed between IgG4-RD patients and HC.
|
| format | Article |
| id | doaj-art-5ddafdb245ae4d7d96f4457be0a27907 |
| institution | Kabale University |
| issn | 0048-7449 2240-2683 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj-art-5ddafdb245ae4d7d96f4457be0a279072025-01-23T02:31:36ZengPAGEPress PublicationsReumatismo0048-74492240-26832025-01-0110.4081/reumatismo.2025.1744Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related diseaseLinda Mastromanno0https://orcid.org/0009-0001-3114-8791Federico Giardina1Angelica Gattamelata2Serena Colafrancesco3Simona Truglia4Francesca Romana Spinelli5Edoardo Simoncelli6Bruno Lucchino7Fabrizio Conti8Roberta Priori9https://orcid.org/0000-0002-6695-1445Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of RomeRheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of RomeRheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of RomeDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, MilanRheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of RomeRheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of RomeRheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of RomeRheumatology Unit, ASST FBF Sacco, MilanRheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of RomeRheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome; Unicamillus, Saint Camillus International University of Health Sciences, Rome Objective. To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with immunoglobulin-G4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-CoV-2 infection in IgG4-RD patients. Methods. Patients with IgG4-RD in follow-up before the onset of the SARS-CoV-2 pandemic were contacted by telephone and asked to answer an ad hoc questionnaire regarding their vaccination status against SARS-CoV-2 and related AEs following vaccination. The occurrence and the outcome of SARS-CoV-2 infection were also recorded. The same questionnaire was proposed to healthy controls (HC). Results. 20 patients and 40 HC were enrolled. In the patient’s cohort, 90% were vaccinated with at least one dose; among them, 9 reported AEs: 44.4% systemic and 22.2% local. Within the HC group, 100% were vaccinated with at least one dose. 13 out of 40 HC had systemic AEs (50%), and 27 (67.5%) reported local AEs. Neither in IgG4-RD nor in HC, serious adverse reactions were observed. Among the patient’s cohort, 60% contracted SARS-CoV-2 infection, and 41.67% were on immunosuppressants at the time of the infection. One patient presented with severe COVID-19. No disease flares following vaccination or infection were reported. Conclusions. Results from our study indicate a good adherence to the vaccination campaign against SARS-CoV-2 in patients with IgG4-RD and support a relatively good safety profile of this vaccine. Compared to controls, patients with IgG4-RD reported slightly more systemic AEs and fewer local AEs. A similar rate of COVID-19 development was observed between IgG4-RD patients and HC. https://www.reumatismo.org/reuma/article/view/1744IgG4-related diseaseSARS-CoV-2COVID-19vaccination |
| spellingShingle | Linda Mastromanno Federico Giardina Angelica Gattamelata Serena Colafrancesco Simona Truglia Francesca Romana Spinelli Edoardo Simoncelli Bruno Lucchino Fabrizio Conti Roberta Priori Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease Reumatismo IgG4-related disease SARS-CoV-2 COVID-19 vaccination |
| title | Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease |
| title_full | Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease |
| title_fullStr | Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease |
| title_full_unstemmed | Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease |
| title_short | Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease |
| title_sort | adherence to vaccination against sars cov 2 and vaccine safety in patients with immunoglobulin g4 related disease |
| topic | IgG4-related disease SARS-CoV-2 COVID-19 vaccination |
| url | https://www.reumatismo.org/reuma/article/view/1744 |
| work_keys_str_mv | AT lindamastromanno adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT federicogiardina adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT angelicagattamelata adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT serenacolafrancesco adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT simonatruglia adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT francescaromanaspinelli adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT edoardosimoncelli adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT brunolucchino adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT fabrizioconti adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease AT robertapriori adherencetovaccinationagainstsarscov2andvaccinesafetyinpatientswithimmunoglobuling4relateddisease |